Sign in
Taking people in United StatesNo phase

Testing MR-guided radiation therapy for several types of cancer

Tests whether MR-guided radiation can be given safely to adults with cancer.

Key facts

Who runs it
Dana-Farber Cancer Institute
Where
Boston, United StatesSee the 2 sites
Trial code
Registry title
Stereotactic Magnetic Resonance Guided Radiation Therapy
Status
Recruiting
People taking part
397 people, planned
Started
22 Oct 2019
Expected to end
Jun 2028
Type of study
Interventional, 19 groups
Treatments tested
  • MR-guided Linac
Record updated
13 November 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a confirmed cancer who need stereotactic body radiation therapy, with a tumor no larger than 7cm (2.8 in). Specific rules for each cancer site are given in separate cohorts.

Age
18 years or older
Sex
All sexes can join
Disease stage
A confirmed cancer that needs stereotactic body radiation therapy; tumor size 7cm (2.8 in) or less. Further details depend on the disease site cohort.

Main reasons for not taking part

  • Allergic reaction to gadolinium-based contrast given into a vein (does not apply if no contrast is used)
  • Pregnancy
  • Severe claustrophobia or anxiety
  • Cannot have an MRI scan

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Participants must have a confirmed malignancy requiring stereotactic body radiation therapy. See specific disease site cohorts for more details
  • Tumor size ≤ 7cm
  • Age 18 years of older
  • ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A)
  • Ability to understand and the willingness to sign a written informed consent document
  • Specific eligibility requirements for each disease site with be covered in each specific cohort

Who cannot take part

  • Specific exclusion requirements for each disease site with be covered in each specific cohort
  • History of allergic reactions attributed to gadolinium-based IV contrast; -- Note: If a patient will not receive contrast, this is not applicable
  • Pregnant women are excluded from this study
  • Severe claustrophobia or anxiety
  • Participants who cannot undergo an MRI

Where in United States

  • Brigham & Women's HospitalBoston, United StatesContact: Jonathan Leeman, MDTaking people
  • Dana-Farber Cancer InstituteBoston, United StatesContact: Jonathan Leeman, MDTaking people

About the trial

What the trial wants to find out

This is a master prospective Phase I-II trial evaluating feasibility and efficacy of stereotactic magnetic resonance (MR) guided adaptive radiation therapy (SMART) in patients with cancer.

Read full original descriptionShow less

* The phase 1 study will evaluate the feasibility and safety of delivering SMART in patients with cancer. * Phase 2 will evaluate efficacy of SMART with specific reference to tumor control and improvement in patient reported outcome measures

The 19 groups in the trial

  • PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--PancreaticTreatment being tested

    SMART will be administered per each individual disease site standards

    Treatment: MR-guided Linac

  • PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--RenalTreatment being tested

    SMART will be administered per each individual disease site standards

    Treatment: MR-guided Linac

  • PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Central LungTreatment being tested

    SMART will be administered per each individual disease site standards

    Treatment: MR-guided Linac

  • PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Adrenal MetastasesTreatment being tested

    SMART will be administered per each individual disease site standards

    Treatment: MR-guided Linac

  • PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Liver MetastasesTreatment being tested

    SMART will be administered per each individual disease site standards

    Treatment: MR-guided Linac

  • PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Metachronous Oligometastatic NodesTreatment being tested

    SMART will be administered per each individual disease site standards

    Treatment: MR-guided Linac

  • PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Oligoprogressive Oligometastatic Nodes/Soft TissueTreatment being tested

    SMART will be administered per each individual disease site standards

    Treatment: MR-guided Linac

  • PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Synchronous Oligometastatic Nodes/Soft TissueTreatment being tested

    SMART will be administered per each individual disease site standards

    Treatment: MR-guided Linac

  • PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--ProstateTreatment being tested

    SMART will be administered per each individual disease site standards

    Treatment: MR-guided Linac

  • PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Borderline Resectable PancreasTreatment being tested

    SMART will be administered per each individual disease site standards

    Treatment: MR-guided Linac

  • PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Brain MetastasesTreatment being tested

    SMART will be administered per each individual disease site standards

    Treatment: MR-guided Linac

  • PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--MesotheliomaTreatment being tested

    SMART will be administered per each individual disease site standards

    Treatment: MR-guided Linac

  • PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Prostate BoostTreatment being tested

    SMART will be administered per each individual disease site standards

    Treatment: MR-guided Linac

  • PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Pelvic Re-IrradiationTreatment being tested

    SMART will be administered per each individual disease site standards

    Treatment: MR-guided Linac

  • PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--SpineTreatment being tested

    SMART will be administered per each individual disease site standards

    Treatment: MR-guided Linac

  • PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Single-Fraction Kidney TumorsTreatment being tested

    SMART will be administered per each individual disease site standards

    Treatment: MR-guided Linac

  • PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--1/3 Fraction for Oligometastatases in the Abdomen/PelvisTreatment being tested

    SMART will be administered per each individual disease site standards

    Treatment: MR-guided Linac

  • PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Post-Operative Radiation Therapy in Lung CancerTreatment being tested

    SMART will be administered per each individual disease site standards

    Treatment: MR-guided Linac

  • PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Mediastinal and Hilar Lymph NodesTreatment being tested

    SMART will be administered per each individual disease site standards

    Treatment: MR-guided Linac

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Master Protocol of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy (SMART)
Plain-language title
Testing MR-guided radiation therapy for several types of cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
13 November 2025